The efficacy and safety of risperidone long-acting injectable (LAI) for preventing recurrence
of mood episodes in patients with bipolar I disorder was evaluated in a randomized, placebo …

BACKGROUND: Treatment adherence is a significant problem in patients with bipolar
disorder. This study was designed to determine the efficacy of risperidone long-acting …

Background The objective of this exploratory analysis was to characterize efficacy and onset
of action of a 3-month treatment period with risperidone long-acting injection (RLAI) …

Objectives We explored the effect of risperidone long-acting injection (LAI) treatment on
patients with bipolar I disorder in a real-world setting. Methods In this retrospective cohort …

This study aimed to assess the safety, tolerability, efficacy, and compliance of a risperidone
long-acting injection (RLAI) formulation for the maintenance treatment of stabilized bipolar …

Background: Risperidone is the first atypical antipsychotic to become available in a long-
acting, injectable formulation. This is the first prospective study to assess the effectiveness of …

Objective The aim of this study was to compare the treatment effectiveness between long-
acting injectable risperidone and long-acting injectable first-generation antipsychotics …

Background: Combination therapy (risperidone and a mood stabilizer) for patients with a
history of bipolar disorder (DSM-IV) and hospitalized for treatment of a manic episode was …

Poor adherence to pharmacotherapy during maintenance-phase treatment of bipolar
disorder is a common occurrence, exposing patients to a high risk of illness relapses …

Bipolar disorder is a multidimensional illness typified by fluctuating periods of depression
and mania, cognitive dysfunction, abnormal circadian rhythms, and multiple comorbid …